The process of malignant progression in human breast cancer
- PMID: 2083184
- DOI: 10.1093/oxfordjournals.annonc.a057790
The process of malignant progression in human breast cancer
Abstract
Malignant progression in breast cancer represents the processes through which localized, hormone-dependent tumor cells become resistant to endocrine manipulations and metastasize to sites distant from the primary tumor. By selection in ovariectomized athymic nude mice, we have isolated a variant (MIII) of the hormone-dependent, poorly invasive, human breast cancer cell line MCF-7. MIII cells have lost their absolute requirement for estrogen to form proliferating tumors in nude mice. Furthermore, these tumors are significantly more invasive than the parental MCF-7 cell line. MIII cells retain some responsivity to estrogens and antiestrogens, indicating that they have progressed to a hormone-independent but hormone-esponsive phenotype. In an attempt to determine the nature of this process, we have compared the phenotype of MIII cells with that of other MCF-7 variants. These comparisons strongly suggest that the factors contributing to perturbations in antiestrogen sensitivity, hormone-dependent growth, metastatic potential and tumorigenicity are essentially independent of each other and acquired in a random manner. Loss of estrogen receptor expression and overexpression of EGF receptors tend to occur later in the process of malignant progression.
Similar articles
-
Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression.Breast Cancer Res Treat. 1994;31(2-3):237-48. doi: 10.1007/BF00666157. Breast Cancer Res Treat. 1994. PMID: 7881102 Review.
-
Acquisition of hormone-independent growth in MCF-7 cells is accompanied by increased expression of estrogen-regulated genes but without detectable DNA amplifications.Cancer Res. 1993 Jan 15;53(2):283-90. Cancer Res. 1993. PMID: 8380254
-
Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice.Cancer Res. 1985 Feb;45(2):584-90. Cancer Res. 1985. PMID: 3967234
-
Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 MIII human breast cancer xenografts in athymic nude mice.Cancer. 1994 Feb 15;73(4):1229-38. doi: 10.1002/1097-0142(19940215)73:4<1229::aid-cncr2820730417>3.0.co;2-1. Cancer. 1994. PMID: 8313327
-
The biology of breast tumor progression. Acquisition of hormone independence and resistance to cytotoxic drugs.Acta Oncol. 1992;31(2):115-23. doi: 10.3109/02841869209088890. Acta Oncol. 1992. PMID: 1622625 Review.
Cited by
-
In vitro antineoplastic activity of C7-substituted mitomycin C analogues MC-77 and MC-62 against human breast-cancer cell lines.Cancer Chemother Pharmacol. 1992;29(4):290-6. doi: 10.1007/BF00685947. Cancer Chemother Pharmacol. 1992. PMID: 1537075
-
Tumor Innervation: History, Methodologies, and Significance.Cancers (Basel). 2022 Apr 14;14(8):1979. doi: 10.3390/cancers14081979. Cancers (Basel). 2022. PMID: 35454883 Free PMC article. Review.
-
Hormone resistance, invasiveness, and metastatic potential in breast cancer.Breast Cancer Res Treat. 1993;24(3):227-39. doi: 10.1007/BF01833263. Breast Cancer Res Treat. 1993. PMID: 8435478 Review.
-
Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patients.J Cell Mol Med. 2014 Dec;18(12):2536-52. doi: 10.1111/jcmm.12322. Epub 2014 Oct 7. J Cell Mol Med. 2014. PMID: 25287328 Free PMC article.
-
Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression.Breast Cancer Res Treat. 1994;31(2-3):237-48. doi: 10.1007/BF00666157. Breast Cancer Res Treat. 1994. PMID: 7881102 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical